新型治疗严重哮喘药物:本拉珠单抗

A novel drug in treating severe asthma:benralizumab

嗜酸粒细胞在哮喘的病理生理过程中发挥重要作用,白细胞介素5(IL-5)与嗜酸粒细胞表面的IL-5受体结合后,可调节嗜酸粒细胞的分化、增殖与激活。本拉珠单抗为一人源化Ig G1单克隆抗体,可与IL-5受体α亚基特异性结合。本拉珠单抗由阿斯利康制药公司研发,于2017年11月在美国被批准用于年龄≥12岁嗜酸粒细胞型严重哮喘患者的维持治疗。临床试验表明,本拉珠单抗可改善哮喘症状,降低哮喘年加重率。本拉珠单抗最常见的不良反应有头痛、咽炎等。

Eosinophils play an important role in the pathophysiology of asthma. Interleukin-5（IL-5） is a cytokine involved in regulating the differentiation, proliferation, and activation of eosinophils via the human IL-5 receptor. Benralizumab is a humanized Ig G1 monoclonal antibody selective for IL-5 receptor alpha subunit.It has been developed by Astra Zeneca. In November 2017, benralizumab was approved in USA for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Clinical trials indicate that benralizumab can reduce annual exacerbation rate and improve asthma symptom. The most common adverse reactions include headache, pharyngitis, and so on.